| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 155.6MM | +2% |
| Gross Profit | 67.6MM | +8% |
| Cost Of Revenue | 88MM | -2% |
| Operating Income | -18.6MM | -23% |
| Operating Expenses | 86.2MM | -0% |
| Net Income | -14.3MM | -23% |
| R&D | 7.1MM | +35% |
| G&A | 59.8MM | -3% |
| Marketing | 18.1MM | +3% |
| Amortization | 8.8MM | -0% |
| Interest Expense | 12.3MM | -532% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FT. MYERS, Fla., April 18, 2024--NeoGenomics, Inc., announced two promotions within its senior leadership team, effective immediately.
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
FT. MYERS, Fla., April 09, 2024--NeoGenomics will report its first quarter 2024 financial results on Tuesday, April 30, 2024.
FT. MYERS, Fla., March 27, 2024--NeoGenomics will present data at AACR, showing its commitment to advancing cancer patient care through innovative research & development initiatives.
NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The consensus price target hints at a 43.3% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FT. MYERS, Fla., March 20, 2024--NeoGenomics released its 2023 ESG Report, measuring key sustainability focus areas – quality, integrity, accountability, teamwork, and innovation.
FT. MYERS, Fla., March 01, 2024--NeoGenomics, Inc. will participate in the upcoming TD Cowen 44th Annual Health Care Conference in Boston, Mass.